In lupus-prone (NZB/NZW F1) mice model that was treated with TIGIT-Ig fusion protein, the onset of SLE was delayed, proteinuria and autoantibodies production were reduced, inflammatory response was inhibited and survival was prolonged compared to those of the controls (16). This evidence concerns the gene TIGIT and systemic lupus erythematosus.